Skip to main content
. 2016 Aug 19;6:29176. doi: 10.1038/srep29176

Figure 7. Inhibition of EZH2 activated SFRP1 in OA chondrocytes and delayed OA development in vivo.

Figure 7

(A) EPZ005687, a strong inhibitor of EZH2, enhanced the activity of SFRP1 in human OA chondrocytes shown by Realtime PCR. (B) EPZ005687 revived the inhibited SFRP1 in OA chondrocytes shown by Westernblot. (C) EPZ005687 delayed OA development demonstrated by SO staining. Scale bars, 200 & 50 μm. (D) OARSI scoring of OA severity upon EPZ005687 treatment. The in vivo experiments clearly demonstrated the therapeutic effects of EPZ005687 on OA cartilage degeneration in mice. (E–J) The cartilage samples from sham, OA + EZP205687 and OA + NS group were examined for the expression of COLX, ADAMTS-5, MMP3, MMP13, SFRP1 and β-catenin by Realtime PCR. The results confirmed the protective effect of EPZ005687 on chondrocytes. Values are means ± SD (n = 3). *p < 0.05, **p < 0.01.